At its July 2022 meeting, the State Medical Board of Ohio (SMBO) conducted a review of all COVID-19 waivers. As a result of this review, seven waivers are set to be rescinded effective Wednesday, August 10, including:
- Authorized the extension of emergency refills
- Authorized prescribers working in an opioid treatment program licensed as a terminal distributor of dangerous drugs to temporarily delegate personally furnishing of buprenorphine products to nurses licensed under Chapter 4723. of the Revised Code
- Authorized the use of temporary satellite locations for the storage and use of dangerous drugs during COVID-19
- Authorized the temporary waiver of the 5 percent limit on the occasional wholesale sales of dangerous drugs by a licensed pharmacy set forth in rule 4729:5-3-09 of the Administrative Code
- Temporarily suspends in-person training requirements for obtaining BLS in paragraph (M) of rule 4729:1-3-02 and (A)(3) of rule 4729:2-3-03 of the Administrative Code
- Temporarily expands the pharmacy intern supervision requirements in OAC 4729:2-1-01 for interns administering COVID-19 vaccine
- National Guard personnel assigned to any Ohio-licensed pharmacy may perform technician trainee activities pursuant to rule 4729:3-3-01 of the Ohio Administrative Code and any other COVID-19 waivers issued by the Board under the direct supervision of a pharmacist without registration by the Board.
For more information on the waivers rescinded and the waivers that are still in effect, please review the following updated COVID-19 guidance document.